Skip to Content

Rule

New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Change of Sponsor; Change of Sponsor's Name; Change of Sponsor's Address

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble Start Printed Page 18773

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule; technical amendments.

SUMMARY:

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during January and February 2015. FDA is also informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable. The animal drug regulations are also being amended to reflect several non-substantive changes. These technical amendments are being made to improve the accuracy of the regulations.

DATES:

This rule is effective April 8, 2015, except for the amendment to 21 CFR 522.1004, which is effective April 20, 2015.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9019, george.haibel@fda.hhs.gov.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during January and February 2015, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain these documents at the CVM FOIA Electronic Reading Room: http://www.fda.gov/​AboutFDA/​CentersOffices/​OfficeofFoods/​CVM/​CVMFOIAElectronicReadingRoom/​default.htm. Marketing exclusivity and patent information may be accessed in FDA's publication, Approved Animal Drug Products Online (Green Book) at: http://www.fda.gov/​AnimalVeterinary/​Products/​ApprovedAnimalDrugProducts/​default.htm.

Table 1—Original and Supplemental NADAs and ANADAs Approved During January and February 2015

NADA/ANADASponsorNew animal drug product nameAction21 CFR sectionsFOIA summaryNEPA review
141-435Piedmont Animal Health, 204 Muirs Chapel Rd., Suite 200, Greensboro, NC 27410ADVANTUS (imidacloprid) Chewable TabletsOriginal approval for the treatment of flea infestations on dogs and puppies520.1156yesCE 1 2
141-418Luitpold Pharmaceuticals, Inc., Animal Health Division, Shirley, NY 11967BETAVET (betamethasone sodium phosphate and betamethasone acetate) Injectable SuspensionOriginal approval for the control of pain and inflammation associated with osteoarthritis in horses522.167yesCE 1 2
200-527Putney, Inc., One Monument Sq., suite 400, Portland, ME 04101Enrofloxacin Antibacterial Injectable SolutionOriginal approval as a generic copy of NADA 140-913522.812yesCE 1 3
200-576Akorn Animal Health, Inc., 1925 West Field Ct., suite 300, Lake Forest, IL 60045Gentamicin Sulfate Ophthalmic SolutionOriginal approval as a generic copy of NADA 099-008524.1044ayesCE 1 3
Start Printed Page 18774
141-280 4Intervet, Inc., 556 Morris Ave., Summit, NJ 07901ZILMAX (zilpaterol hydrochloride) plus RUMENSIN (monensin) plus TYLAN (tylosin phosphate) plus MGA (melengestrol acetate) Type A medicated articlesSupplemental approval to provide for component feeding of combination drug Type C medicated feeds to heifers fed in confinement for slaughter558.665yesCE 1 5
141-406Merial, Inc., 3239 Satellite Blvd., Bldg. 500, Duluth, GA 30096-4640NEXGARD (afoxolaner) Chewable TabletsSupplemental approval for the treatment and control of an additional tick species in dogs and puppies520.43yesCE 1 2
1 The Agency has determined that this action is categorically excluded (CE) from the requirement to submit an environmental assessment or an environmental impact statement because it is of a type that does not have a significant effect on the human environment.
2 CE granted under 21 CFR 25.33(d)(1).
3 CE granted under 21 CFR 25.33(a)(1).
4 This application is affected by guidance for industry (GFI) #213, “New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions with GFI #209”, December 2013.
5 CE granted under 21 CFR 25.33(a)(2).

In addition during January and February 2015, ownership of, and all rights and interest in, the following approved applications have been transferred as follows:

NADA/ANADAPrevious sponsorNew animal drug product nameNew sponsor21 CFR Section
141-098Abbott Laboratories, North Chicago, IL 60064PROPOFLO (propofol) Injectable SuspensionZoetis Inc., 333 Portage St., Kalamazoo, MI 49007522.2005
141-103Abbott Laboratories, North Chicago, IL 60064SEVOFLO (sevoflurane) Inhalation AnestheticZoetis Inc., 333 Portage St., Kalamazoo, MI 49007529.2150
141-346Abbott Laboratories, North Chicago, IL 60064OROCAM (meloxicam) Oral SprayZoetis Inc., 333 Portage St., Kalamazoo, MI 49007529.1350
141-434Abbott Laboratories, North Chicago, IL 60064SIMBADOL (buprenorphine) Injectable SolutionZoetis Inc., 333 Portage St., Kalamazoo, MI 49007522.230
200-070Abbott Laboratories, North Chicago, IL 60064ISOFLO (isoflurane) Inhalation AnestheticZoetis Inc., 333 Portage St., Kalamazoo, MI 49007529.1186
048-480ADM Alliance Nutrition., Inc., 1000 North 30th St., Quincy, IL 62305-3115CHLORATET 90 and 100 (chlortetracycline) Type A medicated articlesPharmgate LLC, 161 North Franklin Turnpike, suite 2C, Ramsey, NJ 07446558.128
065-256ADM Alliance Nutrition., Inc., 1000 North 30th St., Quincy, IL 62305-3115CHLORTET-SOLUBLE-O (chlortetracycline) PowderPharmgate LLC, 161 North Franklin Turnpike, suite 2C, Ramsey, NJ 07446520.441
200-197Contemporary Products, Inc., 3788 Elm Springs Rd., Springdale, AR 72764-6067Streptomycin Oral SolutionHuvepharma AD, 5th Floor, 3A Nikolay Haitov Str., 1113 Sofia, Bulgaria520.2158
141-084Novartis Animal Health US, Inc., 3200 Northline Ave., suite 300, Greensboro, NC 27408SENTINEL (milbemycin oxime and lufenuron) FLAVOR TABSVirbac AH, Inc., 3200 Meacham Blvd., Ft. Worth, TX 76137522.1143
141-204Novartis Animal Health US, Inc., 3200 Northline Ave., suite 300, Greensboro, NC 27408SENTINEL (milbemycin oxime and lufenuron) FLAVOR TABS and CAPSTAR (nitenpyram) Tablets Flea Management ProgramVirbac AH, Inc., 3200 Meacham Blvd., Ft. Worth, TX 76137520.1510
141-333Novartis Animal Health US, Inc., 3200 Northline Ave., suite 300, Greensboro, NC 27408SENTINEL SPECTRUM (milbemycin oxime/lufenuron/praziquantel) TabletsVirbac AH, Inc., 3200 Meacham Blvd., Ft. Worth, TX 76137520.1447
141-067OPK Biotech, LLC, 11 and 39 Hurley St., Cambridge, MAOXYGLOBIN (hemoglobin glutamer-200 (bovine))Hemoglobin Oxygen Therapeutics, LLC, 674 Souder Rd., Souderton, PA 18964522.1125
Start Printed Page 18775

At this time, the regulations are being amended to reflect these changes of sponsorship.

In addition, Paladin Labs (USA), Inc., 160 Greentree Dr., Suite 101, Dover, DE 19904 has requested that FDA withdraw approval of NADA 141-075 for ANTIZOL-VET (fomepizole) Injection. Elsewhere in this issue of the Federal Register, FDA gave notice that approval of NADA 141-075, and all supplements and amendments thereto, is withdrawn, effective April 20, 2015. As provided in the regulatory text of this document, the animal drug regulations are being amended to reflect this voluntary withdrawal of approval.

Following these changes of sponsorship and withdrawal of approval, Hemoglobin Oxygen Therapeutics, LLC is now the sponsor of an approved application while OPK Biotech, LLC and Paladin Labs (USA), Inc., are no longer the sponsor of an approved application. Also, Merial Ltd., 3239 Satellite Blvd., Bldg. 500, Duluth, GA 30096-4640, has informed FDA that it has changed its name to Merial, Inc., and Intervet, Inc., 556 Morris Ave., Summit, NJ 07901, has informed FDA that it has changed its address to 2 Giralda Farms, Madison, NJ 07940. Accordingly, § 510.600 (21 CFR 510.600) is being amended to reflect these changes.

In addition, FDA is amending the tables in § 510.600(c) to remove listings for International Nutrition, Inc.; NutriBasics Co.; Seeco Inc.; Southern Micro-Blenders, Inc.; and Wellmark International because these firms are no longer the sponsor of an approved application. These technical amendments are being made to improve the accuracy of the regulations.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

Start List of Subjects

List of Subjects

21 CFR Part 510

  • Administrative practice and procedure
  • Animal drugs
  • Labeling
  • Reporting and recordkeeping requirements

21 CFR Parts 520, 522, 524, and 529

  • Animal drugs

21 CFR Part 558

  • Animal drugs
  • Animal feeds
End List of Subjects

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, 522, 524, 529, and 558 are amended as follows:

Start Part

PART 510—NEW ANIMAL DRUGS

End Part Start Amendment Part

1. The authority citation for 21 CFR part 510 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

End Authority Start Amendment Part

2. Amend § 510.600 as follows:

End Amendment Part Start Amendment Part

a. In the table in paragraph (c)(1), remove the entries for “Contemporary Products, Inc.”, “International Nutrition, Inc.”, “NutriBasics Co.”, “OPK Biotech, LLC”, “Paladin Labs (USA), Inc.”, “Seeco Inc.”, “Southern Micro-Blenders, Inc.”, and “Wellmark International”;

End Amendment Part Start Amendment Part

b. In the table in paragraph (c)(1), revise the entries for “Intervet, Inc.” and “Merial Ltd.”; and add an entry, in alphabetical order, for “Hemoglobin Oxygen Therapeutics, LLC”;

End Amendment Part Start Amendment Part

c. In the table in paragraph (c)(2), remove the entries for “011536”, “043733”, “046129”, and “055462”; and

End Amendment Part Start Amendment Part

d. In the table in paragraph (c)(2), revise the entries for “000061”, “050604”, and “063075”.

End Amendment Part

The additions and revisions read as follows:

Names, addresses, and drug labeler codes of sponsors of approved applications.
* * * * *

(c) * * *

(1) * * *

Firm name and addressDrug labeler code
*    *    *    *    *
Hemoglobin Oxygen Therapeutics, LLC, 674 Souder Rd., Souderton, PA 18964063075
*    *    *    *    *
Intervet, Inc., 2 Giralda Farms, Madison, NJ 07940000061
*    *    *    *    *
Merial, Inc., 3239 Satellite Blvd., Bldg. 500, Duluth, GA 30096-4640050604
*    *    *    *    *

(2) * * *

Drug labeler codeFirm name and address
*    *    *    *    *
000061Intervet, Inc., 2 Giralda Farms, Madison, NJ 07940.
*    *    *    *    *
050604Merial, Inc., 3239 Satellite Blvd., Bldg. 500, Duluth, GA 30096-4640.
*    *    *    *    *
063075Hemoglobin Oxygen Therapeutics, LLC, 674 Souder Rd., Souderton, PA 18964.
*    *    *    *    *
Start Part

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

3. The authority citation for 21 CFR part 520 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority Start Amendment Part

4. In § 520.43, revise paragraph (c)(2) to read as follows:

End Amendment Part
Afoxolaner.
* * * * *

(c) * * *

(2) Indications for use. Kills adult fleas; for the treatment and prevention of flea infestations (Ctenocephalides felis); for the treatment and control of black-legged tick (Ixodes scapularis), American dog tick (Dermacentor variabilis), lone star tick (Amblyomma americanum), and brown dog tick (Rhipicephalus sanguineus) infestations in dogs and puppies 8 weeks of age and older, weighing 4 lb of body weight or greater, for 1 month.

* * * * *
[Amended]
Start Amendment Part

5. In § 520.441, in paragraph (b)(4), remove “012286” and in its place add “069254”.

End Amendment Part Start Amendment Part

6. Add § 520.1156 to read as follows:

End Amendment Part
Imidacloprid.

(a) Specifications. Each chewable tablet contains 7.5 or 37.5 milligrams (mg) imidacloprid.

(b) Sponsor. See No. 000859 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Administer daily one 7.5-mg chewable tablet to dogs weighing 4 to 22 pounds (lb) or one 37.5-mg chewable table to dogs weighing 23 to 110 lb.

(2) Indications for use. Kills adult fleas and is indicated for the treatment of flea infestations on dogs and puppies 10 weeks of age and older and weighing 4 lb or greater.

(3) Limitations. Do not give to puppies younger than 10 weeks of age or to dogs weighing less than 4 lb. Do not give more than one tablet a day.

Start Printed Page 18776
[Amended]
Start Amendment Part

7. In § 520.1443, in paragraph (b), remove “058198” and in its place add “051311”.

End Amendment Part
[Amended]
Start Amendment Part

8. In § 520.1447, in paragraph (b), remove “058198” and in its place add “051311”.

End Amendment Part Start Amendment Part

9. In § 520.1510, in paragraph (d)(1)(ii)(B), remove “§ 520.1446(d)(1) of this chapter” and in its place add “§ 520.1443(d)(1)”; and revise the section heading and paragraph (b) to read as follows:

End Amendment Part
Nitenpyram.
* * * * *

(b) Sponsors. See sponsor numbers in § 510.600(c) of this chapter:

(1) No. 058198 for use as in paragraphs (d)(1)(i)(A), (d)(1)(ii)(A), and (d)(2) of this section.

(2) No. 051311 for use as in paragraphs (d)(1)(i)(B) and (d)(1)(ii)(B) of this section.

* * * * *
[Amended]
Start Amendment Part

10. In § 520.2158, in paragraph (b), remove “Nos. 016592 and 055462” and in its place add “No. 016592”.

End Amendment Part Start Part

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

11. The authority citation for 21 CFR part 522 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority Start Amendment Part

12. Add § 522.167 to read as follows:

End Amendment Part
Betamethasone sodium phosphate and betamethasone acetate.

(a) Specifications. Each milliliter (mL) of suspension contains 6 milligrams (mg) betamethasone (3.15 mg betamethasone sodium phosphate and 2.85 mg betamethasone acetate).

(b) Sponsor. See No. 010797 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. Administer 1.5 mL (9 mg total betamethasone) per joint by intra-articular injection. May be administered concurrently in up to two joints per horse.

(2) Indications for use. For the control of pain and inflammation associated with osteoarthritis in horses.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[Amended]
Start Amendment Part

13. In § 522.230, in paragraph (b), remove “000044” and in its place add “054771”.

End Amendment Part Start Amendment Part

14. In § 522.812, add paragraph (b)(3) to read as follows:

End Amendment Part
Enrofloxacin.
* * * * *

(b) * * *

(3) No. 026637 for use of product described in paragraph (a)(1) as in paragraph (e)(1) of this section.

* * * * *
[Removed]
Start Amendment Part

15. Remove § 522.1004.

End Amendment Part Start Amendment Part

16. In § 522.2005, remove paragraph (b)(3); and revise paragraph (b)(2) to read as follows:

End Amendment Part
Propofol.
* * * * *

(b) * * *

(2) No. 054771 for use as in paragraph (c) of this section.

* * * * *
Start Part

PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

17. The authority citation for 21 CFR part 524 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority Start Amendment Part

18. Revise § 524.1044a to read as follows:

End Amendment Part
Gentamicin ophthalmic solution.

(a) Specifications. Each milliliter of solution contains gentamicin sulfate equivalent to 3 milligrams of gentamicin.

(b) Sponsors. See Nos. 000061 and 059399 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs and cats—(1) Amount. Administer 1 or 2 drops into the conjunctival sac 2 to 4 times a day.

(2) Indications for use. For the topical treatment of infections of the conjunctiva caused by susceptible bacteria.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Start Part

PART 529—CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

19. The authority citation for 21 CFR part 529 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
[Amended]
Start Amendment Part

20. In § 529.1186, in paragraph (b), remove “000044” and add “054771,” after “012164,”.

End Amendment Part
[Amended]
Start Amendment Part

21. In § 529.1350, in paragraph (b), remove “000074” and in its place add “054771”.

End Amendment Part
[Amended]
Start Amendment Part

22. In § 529.2150, in paragraph (b), remove “000044” and add “054771,” after “012164,”.

End Amendment Part Start Part

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

End Part Start Amendment Part

23. The authority citation for 21 CFR part 558 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b, 371.

End Authority
[Amended]
Start Amendment Part

24. Amend § 558.128 as follows:

End Amendment Part Start Amendment Part

a. In paragraph (b)(2), remove “No. 012286” and in its place add “No. 069254”;

End Amendment Part Start Amendment Part

b. In paragraph (e)(3)(iv), in the “Limitations” column, remove “012286” and in its place add “069254”; and

End Amendment Part Start Amendment Part

c. In the tables in paragraphs (e)(1), (e)(2), (e)(3), and (e)(4), in the “Sponsor” column, remove “012286,” wherever it occurs.

End Amendment Part Start Amendment Part

25. In § 558.665, add paragraph (e)(9) to read as follows:

End Amendment Part
Zilpaterol.
* * * * *

(e) * * *

Start Printed Page 18777
Zilpaterol in grams/tonCombination in grams/tonIndications for useLimitationsSponsor
*         *         *         *         *         *         *
(9) 6.8 to 24Monensin 10 to 40, plus tylosin 8 to 10, plus melengestrol acetate to provide 0.25 to 0.5 mg/head/dayHeifers fed in confinement for slaughter: For increased rate of weight gain, improved feed efficiency, and increased carcass leanness in cattle fed in confinement for slaughter during the last 20 to 40 days on feed; for prevention and control of coccidiosis due to Eimeria bovis and E. zuernii; and for reduction of incidence of liver abscesses caused by Fusobacterium necrophorum and Arcanobacterium (Actinomyces) pyogenes; and for suppression of estrus (heat)Feed continuously to heifers during the last 20 to 40 days on feed to provide 60 mg zilpaterol hydrochloride per head per day. See §§ 558.342(d), 558.355(d), and 558.625(c). Monensin and tylosin as provided by No. 000986; melengestrol acetate as provided by No. 054771 in § 510.600(c) of this chapter. Withdrawal period: 3 days000061
Start Signature

Dated: April 3, 2015.

Bernadette Dunham,

Director, Center for Veterinary Medicine.

End Signature End Supplemental Information

[FR Doc. 2015-08025 Filed 4-7-15; 8:45 am]

BILLING CODE 4164-01-P